PMC:7665480 / 6945-10394 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"154","span":{"begin":57,"end":65},"obj":"Species"},{"id":"155","span":{"begin":71,"end":79},"obj":"Disease"},{"id":"179","span":{"begin":1675,"end":1678},"obj":"Gene"},{"id":"180","span":{"begin":80,"end":87},"obj":"Species"},{"id":"181","span":{"begin":91,"end":98},"obj":"Species"},{"id":"182","span":{"begin":102,"end":109},"obj":"Species"},{"id":"183","span":{"begin":113,"end":120},"obj":"Species"},{"id":"184","span":{"begin":124,"end":131},"obj":"Species"},{"id":"185","span":{"begin":135,"end":142},"obj":"Species"},{"id":"186","span":{"begin":1751,"end":1761},"obj":"Chemical"},{"id":"187","span":{"begin":1924,"end":1943},"obj":"Chemical"},{"id":"188","span":{"begin":374,"end":386},"obj":"Disease"},{"id":"189","span":{"begin":441,"end":458},"obj":"Disease"},{"id":"190","span":{"begin":559,"end":563},"obj":"Disease"},{"id":"191","span":{"begin":584,"end":590},"obj":"Disease"},{"id":"192","span":{"begin":901,"end":909},"obj":"Disease"},{"id":"193","span":{"begin":939,"end":944},"obj":"Disease"},{"id":"194","span":{"begin":965,"end":984},"obj":"Disease"},{"id":"195","span":{"begin":1005,"end":1012},"obj":"Disease"},{"id":"196","span":{"begin":1061,"end":1069},"obj":"Disease"},{"id":"197","span":{"begin":1090,"end":1099},"obj":"Disease"},{"id":"198","span":{"begin":1199,"end":1208},"obj":"Disease"},{"id":"199","span":{"begin":1232,"end":1237},"obj":"Disease"},{"id":"200","span":{"begin":2386,"end":2390},"obj":"Disease"},{"id":"201","span":{"begin":2416,"end":2432},"obj":"Disease"},{"id":"203","span":{"begin":2847,"end":2854},"obj":"Species"},{"id":"210","span":{"begin":3055,"end":3058},"obj":"Gene"},{"id":"211","span":{"begin":3060,"end":3078},"obj":"Gene"},{"id":"212","span":{"begin":2990,"end":2994},"obj":"Disease"},{"id":"213","span":{"begin":2996,"end":3031},"obj":"Disease"},{"id":"214","span":{"begin":3080,"end":3084},"obj":"Disease"},{"id":"215","span":{"begin":3086,"end":3123},"obj":"Disease"}],"attributes":[{"id":"A154","pred":"tao:has_database_id","subj":"154","obj":"Tax:9606"},{"id":"A155","pred":"tao:has_database_id","subj":"155","obj":"MESH:C000657245"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"Gene:1401"},{"id":"A180","pred":"tao:has_database_id","subj":"180","obj":"Tax:9606"},{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"Tax:9606"},{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"Tax:9606"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"Tax:9606"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"Tax:9606"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"Tax:9606"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"MESH:D003404"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"MESH:C558899"},{"id":"A188","pred":"tao:has_database_id","subj":"188","obj":"MESH:D006973"},{"id":"A189","pred":"tao:has_database_id","subj":"189","obj":"MESH:D003920"},{"id":"A190","pred":"tao:has_database_id","subj":"190","obj":"MESH:D029424"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"MESH:D020521"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:C000657245"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:D003371"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"MESH:D004417"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"MESH:D063806"},{"id":"A196","pred":"tao:has_database_id","subj":"196","obj":"MESH:D006261"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"MESH:D012852"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"MESH:D011014"},{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"MESH:D005334"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"MESH:D012128"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"MESH:D002544"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"Tax:9606"},{"id":"A210","pred":"tao:has_database_id","subj":"210","obj":"Gene:1401"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"Gene:1401"},{"id":"A212","pred":"tao:has_database_id","subj":"212","obj":"MESH:D012128"},{"id":"A213","pred":"tao:has_database_id","subj":"213","obj":"MESH:D012128"},{"id":"A214","pred":"tao:has_database_id","subj":"214","obj":"MESH:D029424"},{"id":"A215","pred":"tao:has_database_id","subj":"215","obj":"MESH:D029424"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 1: Main characteristics of the 6 heart transplant patients with COVID-19\nPatient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6\nDemographics\n Age (years) 69 82 65 71 62 50\n Gender Male Male Male Male Male Female\n Time from heart transplant (years) 5 16 11 1 22 13\n Risk factors\n  BMI (kg/m2) 22.4 23.6 24.5 25.3 32.6 21.5\n  Arterial hypertension − + + + + +\n  Dyslipidaemia − + + − + −\n  Diabetes mellitus − − − − − −\n  Former smoker + − − − − −\n  Extracardiac arteriopathy − − − − − −\n  COPD − − − − − −\n  Stroke − − − − − −\n  Malignancy − − + − − +\n  GFR (ml/min) 80 40 71 82 48 85\n  Previous PCI − + − − − −\n  NYHA class I II I I I I\n Immunosuppressive therapy (mg/day)\n  Cyclosporine 120 120 160 200 135 70\n  Mycophenolate 1440 − 1440 1440 1440 −\n  Everolimus − − − − − 2\nCOVID-19 onset\n Presenting symptoms\n  Cough + + + + + +\n  Shortness of breath + + + + + +\n  Myalgia − + + + + +\n  Anosmia − − + + + +\n  Headache − − − − + +\n  Sinusitis − − − − − +\n  Gastrointestinal symptoms − − − − + +\n NPS test + + + + + +\n X-ray pneumonia signs + + + + −\n Fever peak (°C) 38.0 38.6 38.0 39.5 38.5 39.2\n Hospitalization + + + + + −\n SpO2 at admission (%) 91 85 97 78 85\n Worst SpO2 during hospitalization (%) 88 75 88 75 65\n Laboratory results at admission\n  WBC count (cells per 109/l) 10.00 9.24 4.00 7.50 5.90\n  Hb (g/dl) 10.0 13.5 12.0 13.7 13.5\n  Platelets (cells per 109/l) 400 113 215 301 151\n  Lymphocyte (cells per 109/l) 0.35 0.32 0.55 0.90 0.20\n  CRP (mg/dl) 157 140 3.3 72 29\n  PCT (ng/ml) 0.26 0.09 0 0\n  Serum creatinine (mg/dl) 1.29 2.1 1.79 1.3 2\n  Troponin I (ng/dl) 34 8 18 24\n LVEF (%) 55 45 70 55 50\nTreatment and outcomes\n Hydroxychloroquine + + + + + −\n Lopinavir/ritonavir + − − − + −\n Corticosteroid therapy + + + + + −\n Modification of immunosuppressive therapya + + + + + −\n  % Reduction of cyclosporine 40 100 60 50 40 0\n  % Reduction of mycophenolate 75 0 0 50 50 0\n Antibiotics prophylaxis + + + + + +\n ICU stay + − − − +\n  ICU length of stay 18 − − − 2\n High flow O2 − + − + +\n NIV − + − + +\n Intubation + − − − −\n Complications\n  Respiratory − ARDS − − −\n  Neurological Ischaemic stroke − − − −\n  Infective Sepsis − − − −\n In-hospital length of stay 24 10 13 27 24\n Days to negative NPS testb 10 7 15 14c\n Pronation − − − + +\n Discharged − − + + +\n Dead + + − − − −\na In-hospital percentage reduction from last follow-up dose of immunosuppressant.\nb Days from first positive NPS test to first seriate negative NPS test and clinical resolution of symptoms.\nc The patient has been asymptomatic since receiving the results of the first NPS test, which was repeated after 14 days, per government regulations.\nARDS: acute respiratory distress syndrome; BMI: body mass index; CRP: C-reactive protein; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; Hb: haemoglobin; ICU: intensive care unit; LVEF: left ventricular ejection fraction; NIV: non-invasive ventilation; NPS: naso-pharyngeal swab test; NYHA: New York heart association; PCI: percutaneous coronary intervention; PCT: procalcitonin; SpO2: oxygen saturation; WBC: white blood cells."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T13","span":{"begin":374,"end":386},"obj":"Phenotype"},{"id":"T14","span":{"begin":441,"end":458},"obj":"Phenotype"},{"id":"T15","span":{"begin":559,"end":563},"obj":"Phenotype"},{"id":"T16","span":{"begin":584,"end":590},"obj":"Phenotype"},{"id":"T17","span":{"begin":939,"end":944},"obj":"Phenotype"},{"id":"T18","span":{"begin":965,"end":984},"obj":"Phenotype"},{"id":"T19","span":{"begin":1005,"end":1012},"obj":"Phenotype"},{"id":"T20","span":{"begin":1033,"end":1040},"obj":"Phenotype"},{"id":"T21","span":{"begin":1061,"end":1069},"obj":"Phenotype"},{"id":"T22","span":{"begin":1090,"end":1099},"obj":"Phenotype"},{"id":"T23","span":{"begin":1199,"end":1208},"obj":"Phenotype"},{"id":"T24","span":{"begin":1232,"end":1237},"obj":"Phenotype"},{"id":"T25","span":{"begin":2416,"end":2432},"obj":"Phenotype"},{"id":"T26","span":{"begin":2458,"end":2464},"obj":"Phenotype"},{"id":"T27","span":{"begin":3002,"end":3022},"obj":"Phenotype"},{"id":"T28","span":{"begin":3080,"end":3084},"obj":"Phenotype"},{"id":"T29","span":{"begin":3086,"end":3123},"obj":"Phenotype"}],"attributes":[{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0000819"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0001297"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0003326"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0000458"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0000246"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0002140"},{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0100806"},{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A29","pred":"hp_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/HP_0006510"}],"text":"Table 1: Main characteristics of the 6 heart transplant patients with COVID-19\nPatient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6\nDemographics\n Age (years) 69 82 65 71 62 50\n Gender Male Male Male Male Male Female\n Time from heart transplant (years) 5 16 11 1 22 13\n Risk factors\n  BMI (kg/m2) 22.4 23.6 24.5 25.3 32.6 21.5\n  Arterial hypertension − + + + + +\n  Dyslipidaemia − + + − + −\n  Diabetes mellitus − − − − − −\n  Former smoker + − − − − −\n  Extracardiac arteriopathy − − − − − −\n  COPD − − − − − −\n  Stroke − − − − − −\n  Malignancy − − + − − +\n  GFR (ml/min) 80 40 71 82 48 85\n  Previous PCI − + − − − −\n  NYHA class I II I I I I\n Immunosuppressive therapy (mg/day)\n  Cyclosporine 120 120 160 200 135 70\n  Mycophenolate 1440 − 1440 1440 1440 −\n  Everolimus − − − − − 2\nCOVID-19 onset\n Presenting symptoms\n  Cough + + + + + +\n  Shortness of breath + + + + + +\n  Myalgia − + + + + +\n  Anosmia − − + + + +\n  Headache − − − − + +\n  Sinusitis − − − − − +\n  Gastrointestinal symptoms − − − − + +\n NPS test + + + + + +\n X-ray pneumonia signs + + + + −\n Fever peak (°C) 38.0 38.6 38.0 39.5 38.5 39.2\n Hospitalization + + + + + −\n SpO2 at admission (%) 91 85 97 78 85\n Worst SpO2 during hospitalization (%) 88 75 88 75 65\n Laboratory results at admission\n  WBC count (cells per 109/l) 10.00 9.24 4.00 7.50 5.90\n  Hb (g/dl) 10.0 13.5 12.0 13.7 13.5\n  Platelets (cells per 109/l) 400 113 215 301 151\n  Lymphocyte (cells per 109/l) 0.35 0.32 0.55 0.90 0.20\n  CRP (mg/dl) 157 140 3.3 72 29\n  PCT (ng/ml) 0.26 0.09 0 0\n  Serum creatinine (mg/dl) 1.29 2.1 1.79 1.3 2\n  Troponin I (ng/dl) 34 8 18 24\n LVEF (%) 55 45 70 55 50\nTreatment and outcomes\n Hydroxychloroquine + + + + + −\n Lopinavir/ritonavir + − − − + −\n Corticosteroid therapy + + + + + −\n Modification of immunosuppressive therapya + + + + + −\n  % Reduction of cyclosporine 40 100 60 50 40 0\n  % Reduction of mycophenolate 75 0 0 50 50 0\n Antibiotics prophylaxis + + + + + +\n ICU stay + − − − +\n  ICU length of stay 18 − − − 2\n High flow O2 − + − + +\n NIV − + − + +\n Intubation + − − − −\n Complications\n  Respiratory − ARDS − − −\n  Neurological Ischaemic stroke − − − −\n  Infective Sepsis − − − −\n In-hospital length of stay 24 10 13 27 24\n Days to negative NPS testb 10 7 15 14c\n Pronation − − − + +\n Discharged − − + + +\n Dead + + − − − −\na In-hospital percentage reduction from last follow-up dose of immunosuppressant.\nb Days from first positive NPS test to first seriate negative NPS test and clinical resolution of symptoms.\nc The patient has been asymptomatic since receiving the results of the first NPS test, which was repeated after 14 days, per government regulations.\nARDS: acute respiratory distress syndrome; BMI: body mass index; CRP: C-reactive protein; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; Hb: haemoglobin; ICU: intensive care unit; LVEF: left ventricular ejection fraction; NIV: non-invasive ventilation; NPS: naso-pharyngeal swab test; NYHA: New York heart association; PCI: percutaneous coronary intervention; PCT: procalcitonin; SpO2: oxygen saturation; WBC: white blood cells."}

{"project":"LitCovid-sentences","denotations":[{"id":"T61","span":{"begin":0,"end":8},"obj":"Sentence"},{"id":"T62","span":{"begin":10,"end":79},"obj":"Sentence"},{"id":"T63","span":{"begin":80,"end":144},"obj":"Sentence"},{"id":"T64","span":{"begin":145,"end":157},"obj":"Sentence"},{"id":"T65","span":{"begin":158,"end":194},"obj":"Sentence"},{"id":"T66","span":{"begin":195,"end":240},"obj":"Sentence"},{"id":"T67","span":{"begin":241,"end":298},"obj":"Sentence"},{"id":"T68","span":{"begin":299,"end":312},"obj":"Sentence"},{"id":"T69","span":{"begin":313,"end":362},"obj":"Sentence"},{"id":"T70","span":{"begin":363,"end":404},"obj":"Sentence"},{"id":"T71","span":{"begin":405,"end":438},"obj":"Sentence"},{"id":"T72","span":{"begin":439,"end":476},"obj":"Sentence"},{"id":"T73","span":{"begin":477,"end":510},"obj":"Sentence"},{"id":"T74","span":{"begin":511,"end":556},"obj":"Sentence"},{"id":"T75","span":{"begin":557,"end":581},"obj":"Sentence"},{"id":"T76","span":{"begin":582,"end":608},"obj":"Sentence"},{"id":"T77","span":{"begin":609,"end":639},"obj":"Sentence"},{"id":"T78","span":{"begin":640,"end":678},"obj":"Sentence"},{"id":"T79","span":{"begin":679,"end":711},"obj":"Sentence"},{"id":"T80","span":{"begin":712,"end":743},"obj":"Sentence"},{"id":"T81","span":{"begin":744,"end":779},"obj":"Sentence"},{"id":"T82","span":{"begin":780,"end":823},"obj":"Sentence"},{"id":"T83","span":{"begin":824,"end":869},"obj":"Sentence"},{"id":"T84","span":{"begin":870,"end":900},"obj":"Sentence"},{"id":"T85","span":{"begin":901,"end":915},"obj":"Sentence"},{"id":"T86","span":{"begin":916,"end":936},"obj":"Sentence"},{"id":"T87","span":{"begin":937,"end":962},"obj":"Sentence"},{"id":"T88","span":{"begin":963,"end":1002},"obj":"Sentence"},{"id":"T89","span":{"begin":1003,"end":1030},"obj":"Sentence"},{"id":"T90","span":{"begin":1031,"end":1058},"obj":"Sentence"},{"id":"T91","span":{"begin":1059,"end":1087},"obj":"Sentence"},{"id":"T92","span":{"begin":1088,"end":1117},"obj":"Sentence"},{"id":"T93","span":{"begin":1118,"end":1163},"obj":"Sentence"},{"id":"T94","span":{"begin":1164,"end":1191},"obj":"Sentence"},{"id":"T95","span":{"begin":1192,"end":1230},"obj":"Sentence"},{"id":"T96","span":{"begin":1231,"end":1283},"obj":"Sentence"},{"id":"T97","span":{"begin":1284,"end":1318},"obj":"Sentence"},{"id":"T98","span":{"begin":1319,"end":1361},"obj":"Sentence"},{"id":"T99","span":{"begin":1362,"end":1420},"obj":"Sentence"},{"id":"T100","span":{"begin":1421,"end":1453},"obj":"Sentence"},{"id":"T101","span":{"begin":1454,"end":1514},"obj":"Sentence"},{"id":"T102","span":{"begin":1515,"end":1556},"obj":"Sentence"},{"id":"T103","span":{"begin":1557,"end":1611},"obj":"Sentence"},{"id":"T104","span":{"begin":1612,"end":1672},"obj":"Sentence"},{"id":"T105","span":{"begin":1673,"end":1709},"obj":"Sentence"},{"id":"T106","span":{"begin":1710,"end":1742},"obj":"Sentence"},{"id":"T107","span":{"begin":1743,"end":1794},"obj":"Sentence"},{"id":"T108","span":{"begin":1795,"end":1831},"obj":"Sentence"},{"id":"T109","span":{"begin":1832,"end":1861},"obj":"Sentence"},{"id":"T110","span":{"begin":1862,"end":1884},"obj":"Sentence"},{"id":"T111","span":{"begin":1885,"end":1922},"obj":"Sentence"},{"id":"T112","span":{"begin":1923,"end":1961},"obj":"Sentence"},{"id":"T113","span":{"begin":1962,"end":2003},"obj":"Sentence"},{"id":"T114","span":{"begin":2004,"end":2065},"obj":"Sentence"},{"id":"T115","span":{"begin":2066,"end":2119},"obj":"Sentence"},{"id":"T116","span":{"begin":2120,"end":2171},"obj":"Sentence"},{"id":"T117","span":{"begin":2172,"end":2214},"obj":"Sentence"},{"id":"T118","span":{"begin":2215,"end":2239},"obj":"Sentence"},{"id":"T119","span":{"begin":2240,"end":2276},"obj":"Sentence"},{"id":"T120","span":{"begin":2277,"end":2305},"obj":"Sentence"},{"id":"T121","span":{"begin":2306,"end":2325},"obj":"Sentence"},{"id":"T122","span":{"begin":2326,"end":2352},"obj":"Sentence"},{"id":"T123","span":{"begin":2353,"end":2367},"obj":"Sentence"},{"id":"T124","span":{"begin":2368,"end":2399},"obj":"Sentence"},{"id":"T125","span":{"begin":2400,"end":2444},"obj":"Sentence"},{"id":"T126","span":{"begin":2445,"end":2476},"obj":"Sentence"},{"id":"T127","span":{"begin":2477,"end":2524},"obj":"Sentence"},{"id":"T128","span":{"begin":2525,"end":2570},"obj":"Sentence"},{"id":"T129","span":{"begin":2571,"end":2596},"obj":"Sentence"},{"id":"T130","span":{"begin":2597,"end":2623},"obj":"Sentence"},{"id":"T131","span":{"begin":2624,"end":2647},"obj":"Sentence"},{"id":"T132","span":{"begin":2648,"end":2730},"obj":"Sentence"},{"id":"T133","span":{"begin":2731,"end":2839},"obj":"Sentence"},{"id":"T134","span":{"begin":2840,"end":2989},"obj":"Sentence"},{"id":"T135","span":{"begin":2990,"end":3311},"obj":"Sentence"},{"id":"T136","span":{"begin":3312,"end":3449},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 1: Main characteristics of the 6 heart transplant patients with COVID-19\nPatient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6\nDemographics\n Age (years) 69 82 65 71 62 50\n Gender Male Male Male Male Male Female\n Time from heart transplant (years) 5 16 11 1 22 13\n Risk factors\n  BMI (kg/m2) 22.4 23.6 24.5 25.3 32.6 21.5\n  Arterial hypertension − + + + + +\n  Dyslipidaemia − + + − + −\n  Diabetes mellitus − − − − − −\n  Former smoker + − − − − −\n  Extracardiac arteriopathy − − − − − −\n  COPD − − − − − −\n  Stroke − − − − − −\n  Malignancy − − + − − +\n  GFR (ml/min) 80 40 71 82 48 85\n  Previous PCI − + − − − −\n  NYHA class I II I I I I\n Immunosuppressive therapy (mg/day)\n  Cyclosporine 120 120 160 200 135 70\n  Mycophenolate 1440 − 1440 1440 1440 −\n  Everolimus − − − − − 2\nCOVID-19 onset\n Presenting symptoms\n  Cough + + + + + +\n  Shortness of breath + + + + + +\n  Myalgia − + + + + +\n  Anosmia − − + + + +\n  Headache − − − − + +\n  Sinusitis − − − − − +\n  Gastrointestinal symptoms − − − − + +\n NPS test + + + + + +\n X-ray pneumonia signs + + + + −\n Fever peak (°C) 38.0 38.6 38.0 39.5 38.5 39.2\n Hospitalization + + + + + −\n SpO2 at admission (%) 91 85 97 78 85\n Worst SpO2 during hospitalization (%) 88 75 88 75 65\n Laboratory results at admission\n  WBC count (cells per 109/l) 10.00 9.24 4.00 7.50 5.90\n  Hb (g/dl) 10.0 13.5 12.0 13.7 13.5\n  Platelets (cells per 109/l) 400 113 215 301 151\n  Lymphocyte (cells per 109/l) 0.35 0.32 0.55 0.90 0.20\n  CRP (mg/dl) 157 140 3.3 72 29\n  PCT (ng/ml) 0.26 0.09 0 0\n  Serum creatinine (mg/dl) 1.29 2.1 1.79 1.3 2\n  Troponin I (ng/dl) 34 8 18 24\n LVEF (%) 55 45 70 55 50\nTreatment and outcomes\n Hydroxychloroquine + + + + + −\n Lopinavir/ritonavir + − − − + −\n Corticosteroid therapy + + + + + −\n Modification of immunosuppressive therapya + + + + + −\n  % Reduction of cyclosporine 40 100 60 50 40 0\n  % Reduction of mycophenolate 75 0 0 50 50 0\n Antibiotics prophylaxis + + + + + +\n ICU stay + − − − +\n  ICU length of stay 18 − − − 2\n High flow O2 − + − + +\n NIV − + − + +\n Intubation + − − − −\n Complications\n  Respiratory − ARDS − − −\n  Neurological Ischaemic stroke − − − −\n  Infective Sepsis − − − −\n In-hospital length of stay 24 10 13 27 24\n Days to negative NPS testb 10 7 15 14c\n Pronation − − − + +\n Discharged − − + + +\n Dead + + − − − −\na In-hospital percentage reduction from last follow-up dose of immunosuppressant.\nb Days from first positive NPS test to first seriate negative NPS test and clinical resolution of symptoms.\nc The patient has been asymptomatic since receiving the results of the first NPS test, which was repeated after 14 days, per government regulations.\nARDS: acute respiratory distress syndrome; BMI: body mass index; CRP: C-reactive protein; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; Hb: haemoglobin; ICU: intensive care unit; LVEF: left ventricular ejection fraction; NIV: non-invasive ventilation; NPS: naso-pharyngeal swab test; NYHA: New York heart association; PCI: percutaneous coronary intervention; PCT: procalcitonin; SpO2: oxygen saturation; WBC: white blood cells."}